
Sarepta Shares Soar After FDA Reverses Pause For Controversial Gene Therapy Elevidys
Sarepta Shares Soar After FDA Reverses Pause For Controversial Gene Therapy Elevidys
Shares of Sarepta Therapeutics erupted in premarket trading after the Food and Drug Administration (FDA) lifted a voluntary pause on its gene therapy Elevidys, limited to patients who can still
...Далее